The aggregate gross proceeds to the Company from the offering were approximately $2.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company ...

Clarametyx Biosciences will receive $2.6 million from CARB-X to develop CMTX-301, a vaccine designed to prevent bacterial ...

Ear infections are quite common, especially in children but adults can get them too. There are different parts of your ears ...

In this article we are going to find how calcium tablets will help in boosting bone density and we will be explaining the ...

Clarametyx Biosciences Inc. ("Clarametyx"), a biotechnology company developing immune-enabling biologic technologies to combat serious infections associated with biofilms, today announced that CARB-X ...

But the average number and duration of the episodes didn't differ significantly between the groups, and there were no serious ...

(2007) Europe (Maastricht III) PPI (standard dose b.i.d.) Clarithromycin (500 mg b.i.d.) Amoxicillin (1000 mg b.i.d.) or metronidazole (400 mg b.i.d.) 7–14 In populations with less than 15–20% ...

Daan Willocx, Lucia D'Auria, Danica Walsh, Hugo Scherer, Alaa Alhayek, Mostafa M. Hamed, Franck Borel, Eleonora Diamanti, Anna K. H. Hirsch. Fragment Discovery by X-Ray Crystallographic Screening ...

Researchers at McMaster University have discovered a critical vulnerability in drug-resistant bacteria: zinc -- or a lack thereof. In a recent study, published in the journal Nature Microbiology, ...

Dr. Palzkill and his group use a variety of advanced genetic, biochemical, and physical techniques to understand details about the structure and function of both groups of the beta-lactamases and ...

Denenberg, the chief of pediatrics with Corewell, says the Neonatal Intensive Care Unit is nearly at capacity as well.